Emerson Electric vs GE Vernova
EMR and GEV side by side, both in electronic and other electrical equipment and components, except computer equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EMR and GEV compare
GE Vernova is the larger company, worth 2.5 times as much as Emerson Electric ($228B against $92.0B).
On earnings, GE Vernova is cheaper: it trades at 24.5× trailing earnings, against 36.1× for Emerson Electric.
GE Vernova grew revenue faster over the last twelve months (13.0% versus 4.8% for Emerson Electric).
GE Vernova keeps more of each dollar of sales as profit, with a net margin of 23.0% compared with 13.8% at Emerson Electric.
Both pay dividends: Emerson Electric yields 1.3% and GE Vernova 0.17%.
GE Vernova scores higher on the StockData Score (13 against 11 for Emerson Electric), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EMR | GEV |
|---|---|---|
| Size and price | ||
| Market cap | $92.0B | $228B |
| Share price | $164.94 | $857.87 |
| Change, 1 year | 20.9% | 48.4% |
| Change, 5 years | 68.4% | – |
| Beta (5Y) | 1.10 | 1.37 |
| Employees | 71K | 75K |
| StockData Score | ||
| Total score | 11 | 13 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 36.1× | 24.5× (better) |
| P/S | 4.9× (better) | 5.5× |
| P/B | 4.5× (better) | 19.1× |
| EV/EBITDA | 21.6× (better) | 122× |
| P/FCF | 26.6× | 18.4× (better) |
| FCF yield | 3.8% | 5.4% (better) |
| Fair value | $142.44 | – |
| Margin of safety | −15.8% | – |
| Growth | ||
| Revenue growth (TTM) | 4.8% | 13.0% (better) |
| Revenue growth, 5Y average | 1.4% | – |
| Net income growth (TTM) | −2.8% | 724% (better) |
| EPS growth (TTM) | −1.7% | 745% (better) |
| EPS growth, 5Y average | 4.5% | – |
| Profitability | ||
| Gross margin | 53.2% (better) | 20.2% |
| Operating margin | – | 4.3% |
| Net margin | 13.8% | 23.0% (better) |
| FCF margin | 18.6% | 30.1% (better) |
| Return on equity | 12.8% | 91.5% (better) |
| Return on invested capital | – | 135% |
| Financial health | ||
| Debt / equity | 0.64 | 0.24 (better) |
| Net debt / EBITDA | 2.29 (better) | −5.71 |
| Current ratio | 0.90 (better) | 0.85 |
| Altman Z-score | 4.32 (better) | 2.68 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.3% (better) | 0.17% |
| Payout ratio | 47.8% | 4.3% |
| Years of dividend growth | 16 (better) | 1 |
| Dividend growth, 5Y average | 1.1% | – |
| Buyback yield | 1.00% | 2.4% (better) |
| Shareholder yield | 2.3% | 2.5% (better) |
| Ownership | ||
| Held by institutions | 82.5% | 79.8% |
| Held by insiders | 0.30% | 0.10% |
| Insider net buying, 12 months | −$7.9M (better) | −$11.5M |
| Superinvestors holding | 1 | 5 (better) |
| Short interest, % of float | 1.6% | 2.8% |
Go deeper
- EMR stock overview
- EMR income statement
- EMR valuation and score
- GEV stock overview
- GEV income statement
- GEV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.